138 related articles for article (PubMed ID: 34906905)
1. Complement ratios C3bc/C3 and sC5b-9/C5 do not increase the sensitivity of detecting acute complement activation systemically.
Thomas AM; Chaban V; Pischke SE; Orrem HL; Bosnes V; Sunde K; Seljeflot I; Lundqvist C; Nakstad ER; Andersen GØ; Schjalm C; Mollnes TE; Barratt-Due A
Mol Immunol; 2022 Jan; 141():273-279. PubMed ID: 34906905
[TBL] [Abstract][Full Text] [Related]
2. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
3. Activation of the alternative pathway of complement during the acute phase of typical haemolytic uraemic syndrome.
Ferraris JR; Ferraris V; Acquier AB; Sorroche PB; Saez MS; Ginaca A; Mendez CF
Clin Exp Immunol; 2015 Jul; 181(1):118-25. PubMed ID: 25677399
[TBL] [Abstract][Full Text] [Related]
4. Relative inefficiency of terminal complement activation.
Bhakdi S; Fassbender W; Hugo F; Carreno MP; Berstecher C; Malasit P; Kazatchkine MD
J Immunol; 1988 Nov; 141(9):3117-22. PubMed ID: 3262681
[TBL] [Abstract][Full Text] [Related]
5. Complement activation is associated with poor outcome after out-of-hospital cardiac arrest.
Chaban V; Nakstad ER; Stær-Jensen H; Schjalm C; Seljeflot I; Vaage J; Lundqvist C; Benth JŠ; Sunde K; Mollnes TE; Andersen GØ; Pischke SE
Resuscitation; 2021 Sep; 166():129-136. PubMed ID: 34126135
[TBL] [Abstract][Full Text] [Related]
6. Complement activation in patients with systemic lupus erythematosus without nephritis.
Mollnes TE; Haga HJ; Brun JG; Nielsen EW; Sjöholm A; Sturfeldt G; Mårtensson U; Bergh K; Rekvig OP
Rheumatology (Oxford); 1999 Oct; 38(10):933-40. PubMed ID: 10534542
[TBL] [Abstract][Full Text] [Related]
7. Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study.
Fosse E; Thelin S; Svennevig JL; Jansen P; Mollnes TE; Hack E; Venge P; Moen O; Brockmeier V; Dregelid E; Haldén E; Hagman L; Videm V; Pedersen T; Mohr B
Eur J Cardiothorac Surg; 1997 Feb; 11(2):320-7. PubMed ID: 9080162
[TBL] [Abstract][Full Text] [Related]
8. Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock.
Orrem HL; Nilsson PH; Pischke SE; Grindheim G; Garred P; Seljeflot I; Husebye T; Aukrust P; Yndestad A; Andersen GØ; Barratt-Due A; Mollnes TE
ESC Heart Fail; 2018 Jun; 5(3):292-301. PubMed ID: 29424484
[TBL] [Abstract][Full Text] [Related]
9. Alterations in C3, C4, factor B, and related metabolites in septic shock.
Lin RY; Astiz ME; Saxon JC; Saha DC; Rackow EC
Clin Immunol Immunopathol; 1993 Nov; 69(2):136-42. PubMed ID: 8403550
[TBL] [Abstract][Full Text] [Related]
10. Complement Activation Is Associated With Mortality in Patients With Necrotizing Soft-Tissue Infections-A Prospective Observational Study.
Kristensen MK; Hansen MB; Madsen MB; Hansen CB; Pilely K; Hyldegaard O; Garred P
Front Immunol; 2020; 11():17. PubMed ID: 32082310
[No Abstract] [Full Text] [Related]
11. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients.
Vallhonrat H; Williams WW; Cosimi AB; Tolkoff-Rubin N; Ginns LC; Wain JC; Preffer F; Olszak I; Wee S; Delmonico FL; Pascual M
Transplantation; 1999 Jan; 67(2):253-8. PubMed ID: 10075589
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.
Wehling C; Amon O; Bommer M; Hoppe B; Kentouche K; Schalk G; Weimer R; Wiesener M; Hohenstein B; Tönshoff B; Büscher R; Fehrenbach H; Gök ÖN; Kirschfink M
Clin Exp Immunol; 2017 Feb; 187(2):304-315. PubMed ID: 27784126
[TBL] [Abstract][Full Text] [Related]
13. SC5b-9 is the most sensitive marker in assessing disease activity in Brazilian SLE patients.
Chiu YY; Nisihara RM; Würzner R; Kirschfink M; de Messias-Reason IJ
J Investig Allergol Clin Immunol; 1998; 8(4):239-44. PubMed ID: 9777539
[TBL] [Abstract][Full Text] [Related]
14. Identification of a human C5 beta-chain epitope exposed in the native complement component but concealed in the SC5b-9 complex.
Mollnes TE; Klos A; Tschopp J
Scand J Immunol; 1988 Sep; 28(3):307-12. PubMed ID: 2461581
[TBL] [Abstract][Full Text] [Related]
15. Activation and deposition of human breast-milk complement C3 opsonins on serum sensitive Escherichia coli 0111.
Ogundele MO
J Reprod Immunol; 2000; 48(2):99-105. PubMed ID: 11011075
[TBL] [Abstract][Full Text] [Related]
16. Human monocyte spreading induced by factor Bb of the alternative pathway of complement activation. A possible role for C5 in monocyte spreading.
Sundsmo JS; Götze O
J Exp Med; 1981 Sep; 154(3):763-77. PubMed ID: 6912276
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of detection of complement activation products in evaluating SLE activity.
Nagy G; Brózik M; Varga L; Füst G; Kirschfink M; Kiss E; Gergely P
Lupus; 2000; 9(1):19-25. PubMed ID: 10713643
[TBL] [Abstract][Full Text] [Related]
18. How do complement components and fragments affect cellular immunological function?
Gelfand JA
J Trauma; 1984 Sep; 24(9 Suppl):S118-24. PubMed ID: 6332921
[No Abstract] [Full Text] [Related]
19. Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis.
Brodeur JP; Ruddy S; Schwartz LB; Moxley G
Arthritis Rheum; 1991 Dec; 34(12):1531-7. PubMed ID: 1747138
[TBL] [Abstract][Full Text] [Related]
20. Autoantibody-mediated arthritis in the absence of C3 and activating Fcγ receptors: C5 is activated by the coagulation cascade.
Auger JL; Haasken S; Binstadt BA
Arthritis Res Ther; 2012 Dec; 14(6):R269. PubMed ID: 23237573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
